ReviewBMC geriatrics2013
Assessment of vaccine candidates for persons aged 50 and older: a review.
Review in BMC geriatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).Human vaccines & immunotherapeutics · 2016Guideline
- Adult immunization practices, challenges and opportunities in Central America and the Caribbean: Advisory board proceedings.Human vaccines & immunotherapeutics · 2022Article
- Article
- Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality.Trends in endocrinology and metabolism: TEM · 2020Review
- Influenza-Mediated Lung Infection Models.Methods in molecular biology (Clifton, N.J.) · 2019Article
- The intention of Dutch general practitioners to offer vaccination against pneumococcal disease, herpes zoster and pertussis to people aged 60 years and older.BMC geriatrics · 2017Article
- The cost of vaccination throughout life: A western European overview.Human vaccines & immunotherapeutics · 2016Article
- Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges.PharmacoEconomics · 2016Article
- Onset of Frozen Shoulder Following Pneumococcal and Influenza Vaccinations.Journal of chiropractic medicine · 2015Article
- Sex and Gender Impact Immune Responses to Vaccines Among the Elderly.Physiology (Bethesda, Md.) · 2015Review
- Attitudes of Dutch general practitioners towards vaccinating the elderly: less is more?BMC family practice · 2015Article
- Motives of Dutch persons aged 50 years and older to accept vaccination: a qualitative study.BMC public health · 2015Article
- Vaccination in the elderly: what can be recommended?Drugs & aging · 2014Review
- The effect of aging on the frequency, phenotype and cytokine production of human blood CD4 + CXCR5 + T follicular helper cells: comparison of aged and young subjects.Immunity & ageing : I & A · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing life expectancy in most European countries has resulted in growth of the population 50 and older. This population is more susceptible to infectious diseases because of immunosenescence, co-morbidity and general frailty. Thus, to promote healthy aging, vaccination against vaccine-preventable-diseases could be one strategy. In addition to its possible individual benefits, vaccination may also yield social benefits, such as a lower overall cost of healthcare. Most European countries, however, offer only influenza vaccine although vaccines for pneumococcal disease, herpes zoster, pertussis, and hepatitis A are also available. Our aim is to review the knowledge of these vaccines for persons aged 50 and older and explore the arguments for expanding current vaccination programmes beyond just influenza.
methodsThe evaluation model of Kimman et al. was used to assess herpes zoster, pneumococcal disease, pertussis and hepatitis A in terms of four domains: pathogen, vaccine, disease outcomes and cost-effectiveness. The sources were Dutch surveillance systems, seroprevalence studies and the international literature.
resultsHerpes zoster, pneumococcal disease and pertussis are prevalent among persons aged 50 and older. Vaccines vary in effectiveness and have mild and self-limiting side effects. Vaccination against pneumococcal disease and pertussis causes adaptation of the responsible pathogen. For pertussis and hepatitis A, the vaccine is not registered specifically for the elderly population. Vaccination against herpes zoster and pertussis could improve quality of life, while vaccination against pneumococcal disease and hepatitis A prevents mortality. However, only vaccination against herpes zoster and pneumococcal disease appear to be cost-effective.
conclusionsVaccination can improve the health of the elderly population. As our review shows, however, the data are too incomplete to accurately judge its potential impact. More research is needed to determine how vaccination can most effectively improve the health of the growing population 50 years and older.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.